EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Development of new hormonal male contraception for the couple

Jeffrey M Kroopnick iD, Min S Lee, Diana L Blithe

Andrology · 2024-10 · 12 (7) · 1506-1511

DOI: 10.1111/andr.13654 ↗

At a glance

Übersichtsarbeit in Andrology, published online on 2024-05-15. Written by Jeffrey M Kroopnick and 2 co-authors. Institution: Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA. Major MEDLINE topics: Contraceptive Agents, Male. Cited 11 times so far (Crossref); 32 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Current options for male contraception are limited to condoms, the withdrawal method, or a vasectomy. Studies indicate that men have expressed growing interest in bearing responsibility for family planning.

Objectives

To review prior studies investigating the role of an androgen‐only or androgen with progestin regimen for hormonal male contraception and to provide an update of a promising new hormonal agent, a transdermal gel.

Discussion

Thus far, there have been six studies conducted in couples evaluating the contraceptive efficacy of an androgen‐only or androgen co‐administered with a progestin regimen for hormonal male contraception. The only ongoing study is by the National Institute of Child Health and Human Development, in collaboration with the Population Council. They have developed a novel transdermal gel containing testosterone and segesterone acetate (Nestorone), a progestin. An ongoing phase II study enrolling more than 460 couples has shown great potential with respect to the product's efficacy, safety, reversibility, and acceptability. As this agent advances in development, a rapid at‐home test for sperm concentration will provide couples with immediate feedback regarding their potential for pregnancy.

Conclusion

There is promise for the first‐of‐its‐kind hormonal male contraceptive, a transdermal gel, to achieve market approval for distribution in the United States and elsewhere. Its safety, efficacy, reversibility, and user‐control are all appealing qualities that make it readily adoptable for clinical practice.

Subjects

MeSH terms (MEDLINE)

Contraceptive Agents, MaleHumansMaleTestosteroneHormonal ContraceptionAdministration, CutaneousGelsContraceptive Agents, HormonalNorprogesteronesAndrogens

Author keywords

male contraceptionsegesterone acetatesperm suppressiontestosterone

Substances

Contraceptive Agents, MaleTestosteroneGelsContraceptive Agents, HormonalNorprogesteronesAndrogens

Authors and institutions

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.

ORCID profiles: Jeffrey M Kroopnick

Cite

APA

Kroopnick, J. M., Lee, M. S., & Blithe, D. L. (2024). Development of new hormonal male contraception for the couple. Andrology, 12(7), 1506-1511. https://doi.org/10.1111/andr.13654

Vancouver

Kroopnick JM, Lee MS, Blithe DL. Development of new hormonal male contraception for the couple. Andrology. 2024;12(7):1506-1511. doi:10.1111/andr.13654

BibTeX
@article{Kroopnick2024,
  author = {Kroopnick, Jeffrey M and Lee, Min S and Blithe, Diana L},
  title = {Development of new hormonal male contraception for the couple},
  journal = {Andrology},
  year = {2024},
  volume = {12},
  number = {7},
  pages = {1506--1511},
  doi = {10.1111/andr.13654}
}
Start for free →